Use your browser's print dialog to print or save as PDF. This page is formatted for easy reading on paper.
MyPathologyReport Printed: November 19, 2026

Epithelioid Hemangioendothelioma: Understanding Your Pathology Report

Epithelioid hemangioendothelioma (EHE) is a rare cancer that starts from endothelial cells, the cells that line the inside of blood vessels. It is a type of sarcoma, which is a cancer that starts in the body’s connective tissues. EHE most often develops in the liver, lungs, bones, or soft tissues such as fat and muscle, and most people who are diagnosed with it are adults.

Epithelioid hemangioendothelioma varies widely from person to person. Many tumors grow very slowly and stay stable for years, while a smaller number grow faster and spread to other parts of the body. The findings in your pathology report help your care team understand which pattern your tumor is likely to follow.

This article explains what epithelioid hemangioendothelioma is, how the diagnosis is confirmed, and what the gene fusion, risk features, margins, and stage in your pathology report mean. Our articles on angiosarcoma and Kaposi sarcoma describe other cancers that start from blood vessel cells.

Who gets epithelioid hemangioendothelioma?

Epithelioid hemangioendothelioma is very rare. Fewer than 1 in a million people are diagnosed with it each year. It can occur at almost any age, but most people are diagnosed between their 30s and their 60s, and it is uncommon in children.

EHE that starts in the liver is more common in women, who make up about two-thirds of people with liver EHE. Tumors that carry a less common gene change, called a YAP1::TFE3 fusion, tend to occur in younger adults. This gene change is explained in the section on causes below.

Where in the body does epithelioid hemangioendothelioma develop?

Epithelioid hemangioendothelioma can start almost anywhere in the body, because blood vessels are found in every organ. The liver is the most common site, followed by the lungs, bones, and soft tissues. Less often, it starts in the skin, the lining around the lungs (the pleura), or other organs.

EHE in the skin and soft tissues is usually a single tumor. EHE in the liver, lungs, or bones is often multifocal, which means there are several tumors at the time of diagnosis. More than half of people with EHE have more than one tumor when they are first diagnosed. Genetic studies suggest that these tumors often come from one original tumor that has spread, rather than many separate cancers.

What causes epithelioid hemangioendothelioma?

A gene fusion causes epithelioid hemangioendothelioma. A fusion forms when a piece of one gene breaks off and joins a piece of another gene. The result is a new hybrid gene that does not exist in normal cells. This change happens by chance inside the tumor cells during a person’s life, so it is not inherited and cannot be passed on to children.

About 9 in 10 tumors carry a fusion between two genes called WWTR1 and CAMTA1, and about 1 in 20 carry a fusion between YAP1 and TFE3 instead. The proteins made from WWTR1 and YAP1 normally act like switches that tell a cell when to grow. In healthy cells, a control system called the Hippo pathway turns these switches off when growth should stop. The fusion protein escapes this control, so the growth signal stays switched on and the cells keep dividing.

No lifestyle or environmental risk factors for epithelioid hemangioendothelioma are known.

What are the symptoms of epithelioid hemangioendothelioma?

The symptoms of epithelioid hemangioendothelioma depend on where the tumor is growing. Because many tumors grow slowly, some people have no symptoms, and the tumor is found on a scan done for another reason. When symptoms do occur, they may include:

How is the diagnosis made?

A pathologist diagnoses epithelioid hemangioendothelioma by examining a tissue sample under a microscope. The tumor is usually first seen on a CT scan, MRI, or ultrasound. A sample is then removed with a needle biopsy guided by imaging, or the whole tumor is removed in an operation called an excision.

Under the microscope, the tumor is made of rounded epithelioid cells. These cells grow in thin cords, strands, and small nests. They sit in a pale background tissue that looks bubbly or glassy, which pathologists describe as myxohyaline stroma. Many tumor cells contain a small clear bubble, called an intracytoplasmic vacuole. The bubble is the cell’s attempt to form a tiny blood vessel, and it sometimes holds a red blood cell. The tumor often starts inside or around a blood vessel and spreads out into the nearby tissue.

Because the tumor cells look like carcinoma cells, the pathologist uses special tests to show they are blood vessel cells. The main test is immunohistochemistry, described in the next section. Many laboratories also perform molecular testing to look for the WWTR1::CAMTA1 or YAP1::TFE3 fusion. The test may be fluorescence in situ hybridization (FISH), an RNA-based test, or next-generation sequencing (NGS). Finding the fusion confirms the diagnosis, which is especially helpful when the tumor looks unusual under the microscope.

Once epithelioid hemangioendothelioma is confirmed, imaging is used to find every site of disease. This usually includes CT of the chest, abdomen, and pelvis, and sometimes MRI or PET. The next section describes the stains used to confirm the diagnosis.

Immunohistochemistry

Immunohistochemistry uses antibodies to show which proteins tumor cells make. In epithelioid hemangioendothelioma, it is used to prove that the tumor cells are endothelial cells and to rule out a carcinoma or another vascular tumor. Your report may list some or all of these results:

Stains vary by laboratory, and not every case needs every stain.

What are the different types of epithelioid hemangioendothelioma?

The current World Health Organization classification (5th edition, 2020) and the College of American Pathologists (CAP) soft tissue protocol divide epithelioid hemangioendothelioma into types based on the gene fusion. Your report may name the type in the diagnosis line:

Older reports may write the fusion with a dash, such as WWTR1-CAMTA1, instead of a double colon. Both forms mean the same thing.

Histologic grade

Epithelioid hemangioendothelioma is not graded. Your pathology report will not include a grade number, and this is expected for this diagnosis.

Instead of a grade, the pathologist describes the microscopic features linked to how EHE behaves. These features may appear on your report:

For EHE in soft tissue, two features together are used to estimate risk. A tumor larger than 3 cm with more than 3 mitotic figures in 50 microscope fields is described as high risk. A tumor without either feature is described as low risk. Some reports use phrases such as “EHE with atypical features” or “high-risk EHE” for these tumors.

Tumor size

The size of an epithelioid hemangioendothelioma is measured in centimeters (cm), and the final size is measured on the tumor removed during surgery rather than on a biopsy. Size is one of the two features used to estimate the risk of spread for EHE in soft tissue, with 3 cm as the important cutoff. Size is also used to decide the tumor stage (pT), with cutoffs at 5, 10, and 15 cm for tumors in the trunk, arms, and legs.

When there are several tumors, the report usually gives the size of the largest one and may also say how many tumors were found.

Tumor extension

Epithelioid hemangioendothelioma in soft tissue often starts in or around a blood vessel and can grow into nearby structures as it enlarges. This spread beyond the original site is called tumor extension. The pathologist examines the tissue removed during surgery to see whether tumor cells have grown into nearby muscle, bone, nerves, larger blood vessels, or organs. Extension into nearby structures can increase the tumor stage (pT) for tumors of the head and neck. It may also affect planning for further surgery or radiation therapy.

Lymphovascular invasion

Lymphovascular invasion means tumor cells have entered a blood vessel or lymphatic channel. For most cancers, this is a separate finding that increases the risk of spread. Epithelioid hemangioendothelioma starts from the cells that line blood vessels, and it often grows inside a vein or along the vessel wall. Tumor cells inside vessels are therefore part of how this tumor normally grows, so lymphovascular invasion is not usually reported as a separate risk feature for EHE.

Surgical margins

A margin is the cut edge of the tissue removed during surgery for epithelioid hemangioendothelioma. The pathologist checks every margin for tumor cells under the microscope. The current CAP soft tissue protocol (version 4.2.0.0, June 2024) reports margins in the following ways:

Some reports also list every margin that is less than 0.5 cm from the tumor. When more than one tumor is removed, as in some liver or lung operations, the margins are described for each tumor.

Lymph nodes

Lymph nodes are small immune organs that filter fluid from tissues throughout the body. Epithelioid hemangioendothelioma spreads to lymph nodes uncommonly, but it does happen. Lymph nodes are therefore not routinely removed and are usually taken only when they appear enlarged or suspicious on imaging.

When lymph nodes are examined, the report states how many were examined and whether any contain tumor cells. Tumor in a lymph node changes the nodal stage from pN0 to pN1, as described in the staging section.

Biomarker and molecular testing

For most patients with epithelioid hemangioendothelioma, there are currently no biomarker tests that directly guide the choice of a specific targeted drug. The molecular test usually performed looks for the WWTR1::CAMTA1 or YAP1::TFE3 fusion. It is used to confirm the diagnosis and type, described above, rather than to direct treatment. Research into drugs that block the effects of these fusions is ongoing.

When the disease is growing or causing symptoms, clinicians may perform broader molecular profiling with next-generation sequencing. This testing can find other genetic changes that might make a patient eligible for a clinical trial. Your oncologist can discuss whether profiling is useful in your situation. Learn more about these tests in our Biomarkers section.

Pathologic stage (pTNM)

Pathologic stage describes the size and spread of epithelioid hemangioendothelioma based on the tissue examined by the pathologist. The AJCC Cancer Staging Manual, 8th edition, stages soft tissue tumors using the pTNM system. This remains the current edition for soft tissue sarcoma and includes tumor stage (pT) and nodal stage (pN). Spread to distant organs (M) is usually determined by imaging rather than by the pathologist.

TNM staging does not fit every case of EHE. The CAP protocol notes that EHE with many tumors in the chest or abdomen is not well suited to pTNM staging. For EHE of the liver or lungs, the report may instead describe the size of the largest tumor and how many tumors and organs are involved. Tumors that start in bone are staged with a separate bone system.

Tumor stage (pT)

The pT categories depend on where the tumor started. The letter “m” may be added to the pT stage, as in pT2(m), when there is more than one tumor.

Trunk and extremities (arms, legs, chest wall, abdominal wall):

Head and neck:

For tumors at any site:

Nodal stage (pN)

The pathologic stage differs from the overall stage group. Your oncologist assigns the overall stage group after combining the pathology results with imaging.

What is the prognosis?

The prognosis for epithelioid hemangioendothelioma ranges widely, from tumors that never cause harm to tumors that spread and shorten life. Many people live for many years with stable disease, even when more than one organ is involved. The main factors that shape the outlook are:

Even a tumor that looks bland under the microscope can come back or spread years later. For this reason, follow-up with regular imaging continues for many years after diagnosis.

What happens after the diagnosis?

Once pathology confirms epithelioid hemangioendothelioma, the next steps depend on several factors. These include where the tumor is, how many sites are involved, whether it is causing symptoms, and the risk features on the report. A sarcoma team usually plans care. This team may include a surgical oncologist or orthopedic oncologist, a medical oncologist, a radiation oncologist, and a liver or thoracic surgeon. An international expert consensus published in 2021 is widely used to guide these decisions. Options the team may consider include:

Follow-up usually includes scans every few months at first, then less often if the disease stays stable. Because epithelioid hemangioendothelioma can return many years later, follow-up often continues long term.

Questions to ask your doctor

Related articles on MyPathologyReport.com